{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:30:46Z","timestamp":1785843046621,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5U01-AI069924-05"],"award-info":[{"award-number":["5U01-AI069924-05"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5U01-AI069924-05"],"award-info":[{"award-number":["5U01-AI069924-05"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["174281"],"award-info":[{"award-number":["174281"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["174281"],"award-info":[{"award-number":["174281"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["174281"],"award-info":[{"award-number":["174281"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The rise of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTI) threatens antiretroviral therapy's long-term success (ART). NNRTIs will remain an essential drug for the management of HIV-1 due to safety concerns associated with integrase inhibitors. We fitted a dynamic transmission model to historical data from 2000 to 2018 in nine countries of southern Africa to understand the mechanisms that have shaped the HIV-1 epidemic and the rise of pretreatment NNRTI resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included data on HIV-1 prevalence, ART coverage, HIV-related mortality, and survey data on pretreatment NNRTI resistance from nine southern Africa countries from a systematic review, UNAIDS and World Bank. Using a Bayesian hierarchical framework, we developed a dynamic transmission model linking data on the HIV-1 epidemic to survey data on NNRTI drug resistance in each country. We estimated the proportion of resistance attributable to unregulated, off-programme use of ART. We examined each national ART programme's vulnerability to NNRTI resistance by defining a fragility index: the ratio of the rate of NNRTI resistance emergence during first-line ART over the rate of switching to second-line ART. We explored associations between fragility and characteristics of the health system of each country.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The model reliably described the dynamics of the HIV-1 epidemic and NNRTI resistance in each country. Predicted levels of resistance in 2018 ranged between 3.3% (95% credible interval 1.9\u20137.1) in Mozambique and 25.3% (17.9\u201333.8) in Eswatini. The proportion of pretreatment NNRTI resistance attributable to unregulated antiretroviral use ranged from 6% (2\u201314) in Eswatini to 64% (26\u201385) in Mozambique. The fragility index was low in Botswana (0.01; 0.0\u20130.11) but high in Namibia (0.48; 0.16\u201310.17), Eswatini (0.64; 0.23\u201311.8) and South Africa (1.21; 0.83\u20139.84). The combination of high fragility of ART programmes and high ART coverage levels was associated with a sharp increase in pretreatment NNRTI resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This comparison of nine countries shows that pretreatment NNRTI resistance can be controlled despite high ART coverage levels. This was the case in Botswana, Mozambique, and Zambia, most likely because of better HIV care delivery, including rapid switching to second-line ART of patients failing first-line ART.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06757-6","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T11:36:00Z","timestamp":1633606560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study"],"prefix":"10.1186","volume":"21","author":[{"given":"Julien","family":"Riou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bertagnolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D.","family":"Kouyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"L. Althaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"6757_CR1","unstructured":"WHO. HIV drug resistance report 2019. WHO http:\/\/www.who.int\/hiv\/pub\/drugresistance\/hivdr-report-2019\/en\/."},{"key":"6757_CR2","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/S2352-3018(16)30087-X","volume":"3","author":"H Wang","year":"2016","unstructured":"Wang H, et al. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980\u20132015: the Global Burden of Disease Study 2015. Lancet HIV. 2016;3:e361\u201387.","journal-title":"Lancet HIV"},{"key":"6757_CR3","unstructured":"WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. (WHO, 2016)."},{"key":"6757_CR4","unstructured":"UNAIDS data 2020. http:\/\/rstesa.unaids.org\/documents\/country-snapshots\/83-unaids-data-2020\/file."},{"key":"6757_CR5","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","volume":"380","author":"RK Gupta","year":"2012","unstructured":"Gupta RK, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012;380:1250\u20138.","journal-title":"Lancet"},{"key":"6757_CR6","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1016\/S2352-3018(15)00087-9","volume":"2","author":"AD Haas","year":"2015","unstructured":"Haas AD, et al. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: Collaborative analysis. Lancet HIV. 2015;2:e271\u20138.","journal-title":"Lancet HIV"},{"key":"6757_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","volume":"11","author":"L Wittkop","year":"2011","unstructured":"Wittkop L, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11:363\u201371.","journal-title":"Lancet Infect Dis"},{"key":"6757_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1473-3099(11)70255-9","volume":"12","author":"RL Hamers","year":"2012","unstructured":"Hamers RL, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012;12:307\u201317.","journal-title":"Lancet Infect Dis"},{"key":"6757_CR9","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1016\/S2352-3018(16)30119-9","volume":"3","author":"S \u00c1vila-R\u00edos","year":"2016","unstructured":"\u00c1vila-R\u00edos S, et al. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey. Lancet HIV. 2016;3:e579\u201391.","journal-title":"Lancet HIV"},{"issue":"3","key":"6757_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","volume":"18","author":"RK Gupta","year":"2018","unstructured":"Gupta RK, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346\u201355.","journal-title":"Lancet Infect Dis."},{"key":"6757_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905230","author":"R Zash","year":"2019","unstructured":"Zash R, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1905230.","journal-title":"N Engl J Med"},{"key":"6757_CR12","first-page":"527","volume":"76","author":"J Norwood","year":"2017","unstructured":"Norwood J, et al. Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based Regimens. JAIDS. 2017;76:527\u201331.","journal-title":"JAIDS"},{"key":"6757_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1473-3099(20)30117-1","volume":"20","author":"L Chouchana","year":"2020","unstructured":"Chouchana L, Pariente A, Pannier E, Tsatsaris V, Treluyer J-M. Dolutegravir and neural tube defects: a new insight. Lancet Infect Dis. 2020;20:405\u20136.","journal-title":"Lancet Infect Dis"},{"key":"6757_CR14","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.1016\/S2352-3018(18)30093-6","volume":"5","author":"J Dorward","year":"2018","unstructured":"Dorward J, et al. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV. 2018;5:e400\u20134.","journal-title":"Lancet HIV"},{"key":"6757_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S2055-6640(20)30347-2","volume":"4","author":"R de Waal","year":"2018","unstructured":"de Waal R, et al. HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. J Virus Erad. 2018;4:55\u20138.","journal-title":"J Virus Erad"},{"key":"6757_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.chom.2019.06.010","volume":"26","author":"DA Collier","year":"2019","unstructured":"Collier DA, Monit C, Gupta RK. The impact of HIV-1 drug escape on the global treatment landscape. Cell Host Microbe. 2019;26:48\u201360.","journal-title":"Cell Host Microbe"},{"key":"6757_CR17","doi-asserted-by":"crossref","unstructured":"zur Wiesch, P. A., Kouyos, R., Engelst\u00e4dter, J., Regoes, R. R. & Bonhoeffer, S. Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect Dis 2011; 11, 236\u2013247.","DOI":"10.1016\/S1473-3099(10)70264-4"},{"key":"6757_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","volume":"16","author":"TenoRes Study Group","year":"2016","unstructured":"TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016;16:565\u201375.","journal-title":"Lancet Infect Dis"},{"key":"6757_CR19","first-page":"961","volume":"1","author":"J Gregson","year":"2016","unstructured":"Gregson J, et al. Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. Lancet Infect Dis. 2016;1:961\u20135.","journal-title":"Lancet Infect Dis"},{"key":"6757_CR20","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMra025195","volume":"350","author":"F Clavel","year":"2004","unstructured":"Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023\u201335.","journal-title":"N Engl J Med"},{"key":"6757_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1310\/hct0805-282","volume":"8","author":"F Maggiolo","year":"2007","unstructured":"Maggiolo F, et al. Effect of Adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8:282\u201392.","journal-title":"HIV Clin Trials"},{"key":"6757_CR22","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5","volume":"5","author":"RL Hamers","year":"2018","unstructured":"Hamers RL, de Wit TF, Holmes CB. HIV drug resistance in low-income and middle-income countries. Lancet HIV. 2018;5:e588\u201396.","journal-title":"Lancet HIV"},{"key":"6757_CR23","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1056\/NEJM200003303421303","volume":"342","author":"TC Quinn","year":"2000","unstructured":"Quinn TC, et al. Viral Load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921\u20139.","journal-title":"N Engl J Med"},{"key":"6757_CR24","unstructured":"World Bank. Health Nutrition and Population Statistics. https:\/\/databank.worldbank.org\/source\/health-nutrition-and-population-statistics."},{"key":"6757_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/cid\/ciu223","volume":"59","author":"V Supervie","year":"2014","unstructured":"Supervie V, Viard J-P, Costagliola D, Breban R. Heterosexual risk of HIV transmission per sexual act under combined antiretroviral therapy: systematic review and bayesian modeling. Clin Infect Dis. 2014;59:115\u201322.","journal-title":"Clin Infect Dis"},{"key":"6757_CR26","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1128\/JVI.02579-07","volume":"82","author":"SJ Little","year":"2008","unstructured":"Little SJ, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol. 2008;82:5510\u20138.","journal-title":"J Virol"},{"key":"6757_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v076.i01","volume":"76","author":"B Carpenter","year":"2017","unstructured":"Carpenter B, et al. Stan: a probabilistic programming language. J Stat Softw. 2017;76:1\u201332.","journal-title":"J Stat Softw"},{"key":"6757_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/rssa.12378","volume":"182","author":"J Gabry","year":"2019","unstructured":"Gabry J, Simpson D, Vehtari A, Betancourt M, Gelman A. Visualization in Bayesian workflow. J R Stat Soc A Stat Soc. 2019;182:389\u2013402.","journal-title":"J R Stat Soc A Stat Soc"},{"key":"6757_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12981-019-0220-8","volume":"16","author":"SE Rutstein","year":"2019","unstructured":"Rutstein SE, et al. High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up. AIDS Res Ther. 2019;16:5.","journal-title":"AIDS Res Ther"},{"key":"6757_CR30","doi-asserted-by":"publisher","first-page":"e0188606","DOI":"10.1371\/journal.pone.0188606","volume":"12","author":"J Coetzee","year":"2017","unstructured":"Coetzee J, et al. HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study. PLoS ONE. 2017;12:e0188606.","journal-title":"PLoS ONE"},{"key":"6757_CR31","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1073\/pnas.95.20.11514","volume":"95","author":"TB Kepler","year":"1998","unstructured":"Kepler TB, Perelson AS. Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc Natl Acad Sci USA. 1998;95:11514\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 1","key":"6757_CR32","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1093\/cid\/ciu299","volume":"59","author":"JB Nachega","year":"2014","unstructured":"Nachega JB, et al. Addressing the Achilles\u2019 heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clin Infect Dis. 2014;59(Suppl 1):S21-27.","journal-title":"Clin Infect Dis"},{"key":"6757_CR33","first-page":"56","volume":"17","author":"JM Llibre","year":"2015","unstructured":"Llibre JM, et al. Genetic barrier to resistance for dolutegravir. AIDS Rev. 2015;17:56\u201364.","journal-title":"AIDS Rev"}],"updated-by":[{"DOI":"10.1186\/s12879-021-06791-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000}}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06757-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06757-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06757-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T07:05:53Z","timestamp":1635145553000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06757-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6757"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06757-6","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12879-021-06791-4","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"assertion":[{"value":"17 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12879-021-06791-4","URL":"https:\/\/doi.org\/10.1186\/s12879-021-06791-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1042"}}